Cargando…

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175

Shortened current direct-acting antiviral (DAA) therapies while less expensive, have not provided satisfactory efficacy in naïve cirrhotics, treatment experienced non-cirrhotics or even genotype-3 (GT3)-infected patients. Since DAA regimens consist of the same classes of inhibitors—NS5A (NS5Ai) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallay, Philippe A., Chatterji, Udayan, Bobardt, Michael D., Long, Zhengyu, Zhang, Shengli, Su, Zhuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841536/ https://www.ncbi.nlm.nih.gov/pubmed/27104614 http://dx.doi.org/10.1371/journal.pone.0152036

Ejemplares similares

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
por: Bobardt, Michael, et al.
Publicado: (2014)

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection
por: Chatterji, Udayan, et al.
Publicado: (2016)

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
por: Gallay, Philippe A., et al.
Publicado: (2015)

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
por: Gallay, Philippe, et al.
Publicado: (2019)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
por: Stauffer, Winston, et al.
Publicado: (2023)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
por: Stauffer, Winston, et al.
Publicado: (2023)

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
por: Kuo, Joseph, et al.
Publicado: (2019)

Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
por: Phillips, Sandra, et al.
Publicado: (2015)

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance
por: Bobardt, Michael, et al.
Publicado: (2021)

HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex Formation
por: Gawlik, Katarzyna, et al.
Publicado: (2014)

Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection
por: Hansson, Magnus Joakim, et al.
Publicado: (2015)

The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020)

ST Genesia reference values of 117 healthy donors measured with STG‐BleedScreen, STG‐DrugScreen and STG‐ThromboScreen reagents
por: Ninivaggi, Marisa, et al.
Publicado: (2020)

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019)

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
por: Coelmont, Lotte, et al.
Publicado: (2010)

Cyclophilin Inhibitors as a Novel HCV Therapy
por: Tang, Hengli
Publicado: (2010)

Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture
por: de Wilde, Adriaan H., et al.
Publicado: (2018)

Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
por: Lin, Kai, et al.
Publicado: (2013)

Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection
por: Hopkins, Sam, et al.
Publicado: (2012)

The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication
por: Foster, R.T., et al.
Publicado: (2017)

Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
por: Bobardt, Michael, et al.
Publicado: (2020)

HSV Neutralization by the Microbicidal Candidate C5A
por: de Witte, Lot, et al.
Publicado: (2011)

Cyclophilins and cyclophilin inhibitors in nidovirus replication
por: de Wilde, Adriaan H., et al.
Publicado: (2018)

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120
por: Binley, James M, et al.
Publicado: (2007)

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120
por: Binley, James M, et al.
Publicado: (2006)

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
por: Kuo, Joseph, et al.
Publicado: (2019)

Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma
por: Simón Serrano, Sonia, et al.
Publicado: (2022)

Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma
por: Simón Serrano, Sonia, et al.
Publicado: (2021)

STG-Net: A COVID-19 prediction network based on multivariate spatio-temporal information
por: Song, Yucheng, et al.
Publicado: (2023)

Development and Evaluation of an Enzyme-Linked Immunosorbent Assay for Dengue Capsid
por: Selvarajah, Suganya, et al.
Publicado: (2012)

Assessment of the analytical performances and sample stability on ST Genesia system using the STG‐DrugScreen application
por: Douxfils, Jonathan, et al.
Publicado: (2019)

O4.4. REAL TIME FMRI NEUROFEEDBACK TARGETING STG AND DMN REDUCES AUDITORY HALLUCINATIONS
por: Niznikiewicz, Margaret, et al.
Publicado: (2020)

Cyclophilin inhibitors as antiviral agents
por: Peel, Michael, et al.
Publicado: (2013)

Non‐Immunosuppressive Cyclophilin Inhibitors
por: Schiene‐Fischer, Cordelia, et al.
Publicado: (2022)

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis
por: Simón Serrano, Sonia, et al.
Publicado: (2019)

Emergence of a Streptococcus dysgalactiae subspecies equisimilis stG62647-lineage associated with severe clinical manifestations
por: Oppegaard, Oddvar, et al.
Publicado: (2017)

Epidemiological and Clinical Features of Streptococcus dysgalactiae ssp. equisimilis stG62647 and Other emm Types in Germany
por: Itzek, Andreas, et al.
Publicado: (2023)

Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity
por: Nevers, Quentin, et al.
Publicado: (2018)

Cyclophilin and Viruses: Cyclophilin as a Cofactor for Viral Infection and Possible Anti-Viral Target
por: Watashi, Koichi, et al.
Publicado: (2007)

Suppression of Coronavirus Replication by Cyclophilin Inhibitors
por: Tanaka, Yoshikazu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7me995gh00pok6qj8qep791fsj